S. Schulman

S. Schulman, 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long‐term secondary prevention of venous thromboembolism

S. Schulman, P. Wessman, H. Eriksson, 2006, British journal of haematology.

Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation

R. Beyth, S. Schulman, 2005 .

Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy.

S. Schulman, M. Holmström, A. Majeed, 2012, Thrombosis research.

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

S. Goldhaber, S. Schulman, David Baanstra, 2013, The New England journal of medicine.

Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis

H. Büller, P. Prandoni, G. Wells, 2017, BMJ Open.

Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide

J. Douketis, S. Schulman, E. Jamula, 2008, Journal of thrombosis and haemostasis : JTH.

Venous thromboembolism: Past, present and future

W. Ageno, S. Schulman, S. Konstantinides, 2017, Thrombosis and Haemostasis.

Update on the Treatment of Venous Thromboembolism

S. Schulman, 2016, Seminars in Thrombosis and Hemostasis.

Selective d-Dimer Testing for Diagnosis of a First Suspected Episode of Deep Venous Thrombosis

J. Douketis, M. O’Donnell, S. Kahn, 2013, Annals of Internal Medicine.

Accuracy and safety of (99m)Tc-labeled anti-D-dimer (DI-80B3) Fab' fragments (ThromboView®) in the diagnosis of deep vein thrombosis: a phase II study.

J. Douketis, R. Taillefer, M. Levine, 2012, Thrombosis research.

Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

G. Raskob, R. Beyth, M. Levine, 2004, Chest.

Prophylaxis of Venous Thromboembolism in Patients with Infectious Disease

S. Schulman, H. Hwang, G. Lim, 2020, Tuberculosis and respiratory diseases.

Respiratory Review of 2013: Pulmonary Thromboembolism

S. Schulman, H. Hwang, 2013, Tuberculosis and respiratory diseases.

Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis

S. Schulman, J. Ginsberg, C. Kearon, 2006, The Lancet.

Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model.

A. Skene, J. Halperin, A. Turpie, 2011, Blood.

The absence of `minor' risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios

S. Schulman, K. Meijer, 2009, Journal of thrombosis and haemostasis : JTH.

Management of recurrent venous thromboembolism in patients with cancer: A review.

S. Schulman, Siavash Piran, 2018, Thrombosis research.

Management of venous thromboembolism: an update

S. Schulman, Siavash Piran, 2016, Thrombosis Journal.

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

H. Krumholz, W. Ageno, G. Stone, 2020, Thrombosis and Haemostasis.

Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.

S. Schulman, P. Lindmarker, 2000, The New England journal of medicine.

Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort

J. Douketis, J. Eikelboom, S. Schulman, 2022, Research and practice in thrombosis and haemostasis.

Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

B. Ritchie, S. Schulman, M. Crowther, 2018, Thrombosis and Haemostasis.

Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study

S. Schulman, V. Bhagirath, N. Chan, 2018, Research and practice in thrombosis and haemostasis.

Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

B. Ritchie, S. Schulman, M. Crowther, 2018, Thrombosis and Haemostasis.

Direct Oral Anticoagulants in the Real World: Insights into Canadian Health Care Providers’ Understanding of Medication Dosing and Use

S. Schulman, M. Pai, M. Salib, 2017 .

Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.

J. Odeberg, M. Bruzelius, S. Schulman, 2017, Blood.

Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation

J. Halperin, A. Turpie, P. Steg, 2016, Thrombosis and Haemostasis.

Management of bleeding complications in patients with cancer on DOACs.

S. Schulman, A. Majeed, J. Shrum, 2016, Thrombosis research.

New anticoagulants in atrial fibrillation management.

S. Schulman, 2013, Thrombosis research.

C URRENT OPINION Treatment of venous thromboembolism with dabigatran

S. Schulman, 2012 .

Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?

J. Halperin, A. Turpie, C. Kessler, 2012, Journal of thrombosis and haemostasis : JTH.

Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors.

S. Schulman, O. Grottke, 2019, Anesthesiology.

Bleeding Complications and Management on anticoagulant therapy

S. Schulman, 2017, Seminars in Thrombosis and Hemostasis.

Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study.

B. Ritchie, S. Schulman, M. Carrier, 2017, Thrombosis research.

Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events.

S. Yusuf, S. Connolly, J. Eikelboom, 2016, Thrombosis research.

Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report

S. Schulman, G. Landini, R. Cappelli, 2015, Journal of Thrombosis and Thrombolysis.

Clinical practice. Care of patients receiving long-term anticoagulant therapy.

S. Schulman, 2003, The New England journal of medicine.

Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

S. Goldhaber, S. Schulman, David Baanstra, 2009, The New England journal of medicine.

Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.

H. Büller, S. Middeldorp, S. Schulman, 2014, Blood.

Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

S. Schulman, H. Eriksson, K. Wåhlander, 2003, The New England journal of medicine.

Optimal Duration of Oral Anticoagulant Therapy in Venous Thromboembolism

S. Schulman, 1997, Thrombosis and Haemostasis.

Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH

S. Schulman, K. Meijer, N. Khorsand, 2016, Journal of thrombosis and haemostasis : JTH.

Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate

G. Luijckx, S. Schulman, R. Roberts, 2013, Thrombosis and Haemostasis.

Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis.

W. Ageno, H. Schünemann, M. Jaff, 2020, Blood advances.

Venous Thromboembolism in COVID-19

S. Schulman, Yu Hu, S. Konstantinides, 2020, Thrombosis and Haemostasis.

Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices

S. Connolly, J. Eikelboom, S. Cuddy, 2014, Journal of Thrombosis and Thrombolysis.

The plasma concentration of activated protein C appears normal in patients with haemophilia

M. Blombäck, S. Schulman, J. Stenflo, 2009, Haemophilia.

Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.

M. Björkholm, S. Schulman, S. Kristinsson, 2011, Seminars in hematology.

NXY‐059 Does Not Affect Bleeding Time in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled, 3‐Period Crossover Phase I Study

S. Schulman, N. Egberg, G. Englund, 2007, Journal of clinical pharmacology.

Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.

J. Healey, C. Morillo, S. Schulman, 2013, The Canadian journal of cardiology.

The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg

S. Schulman, P. Lindmarker, 2000, Journal of internal medicine.

The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene

B. Wiman, S. Schulman, N. Egberg, 1999, Thrombosis and Haemostasis.

Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study

F. D’Aragon, S. Kahn, M. Afilalo, 2022, BMJ.

Evaluation of low PAI‐1 activity as a risk factor for hemorrhagic diathesis

J. Odeberg, B. Wiman, S. Schulman, 2006, Journal of thrombosis and haemostasis : JTH.

Detection of a new polymorphism in the PAI-1 gene located in the pro-peptide coding region

B. Wiman, S. Schulman, G. Falk, 1999 .

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

A. Dans, S. Schulman, M. Crowther, 2012, Chest.

Validation of a patient decision aid for choosing between dabigatran and warfarin for atrial fibrillation.

A. Holbrook, S. Schulman, E. Pullenayegum, 2013, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.

J. Halperin, P. Steg, A. Turpie, 2022, JAMA.

Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran

S. Schulman, H. Eriksson, K. Wåhlander, 2005, Thrombosis and Haemostasis.

Matching genes with constitution and environment

S. Schulman, 2016, Thrombosis and Haemostasis.

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis.

H. Schünemann, A. Holbrook, D. Witt, 2019, Blood advances.

Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis.

H. Schünemann, R. Beyth, T. Ortel, 2020, Blood advances.

Supplemental patient education for patients taking oral anticoagulants: systematic review and meta‐analysis

A. Holbrook, S. Schulman, P. Wong, 2013, Journal of thrombosis and haemostasis : JTH.

Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short‐term prognosis

W. Ageno, T. Ortel, A. Falanga, 2015, Journal of thrombosis and haemostasis : JTH.

Perioperative Management of Dabigatran: A Prospective Cohort Study.

J. Douketis, S. Solymoss, M. Blostein, 2015, Circulation.

A Comparison of Six Weeks With Six Months of Oral Anticoagulant Therapy After a First Episode of Venous Thromboembolism

S. Schulman, J. Boberg, G. Lärfars, 1996 .

Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment

S. Schulman, A. Clemens, C. Tilke, 2016, European Respiratory Journal.

Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months

O. Linder, S. Schulman, M. Holmström, 2006, Journal of thrombosis and haemostasis : JTH.

NOACs for treatment of venous thromboembolism in clinical practice

W. Ageno, S. Goldhaber, S. Schulman, 2017, Thrombosis and Haemostasis.

Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: Analysis of the BRIDGE trial

V. Hasselblad, J. Douketis, T. Ortel, 2018, American heart journal.

MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial

S. Kahn, S. Schulman, A. Lazo-Langner, 2021, BMJ Open.

Increased urinary transforming growth factor-beta(1) excretion in children with posterior urethral valves.

M. Leonard, K. MacRae Dell, S. Schulman, 2000, Urology.

Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability.

F. D’Aragon, A. Hirsch, M. Afilalo, 2019, The New England journal of medicine.

industry-sponsored clinical trials: the ARO-CRO model Improving academic leadership and oversight in large

A. Skene, J. Halperin, A. Turpie, 2011 .

Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting

S. Kahn, M. Blostein, S. Schulman, 2012, Thrombosis and Haemostasis.

Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation.

A. Holbrook, Sue Troyan, S. Schulman, 2016, Thrombosis research.

Acute Unilateral Renal Infarction in the Setting of an Inherited Thrombophilia and Atrial Septal Defect

S. Schulman, Siavash Piran, 2017, Case reports in hematology.

Definition of major bleeding in surgery: an anesthesiologist’s point of view: reply to a rebuttal

B. Eriksson, D. Bergqvist, S. Schulman, 2010 .

Treatment of acute pulmonary embolism with dabigatran versus warfarin

S. Goldhaber, M. Feuring, S. Schulman, 2016, Thrombosis and Haemostasis.

Rapid quantitative D‐dimer to exclude pulmonary embolism: a prospective cohort management study

J. Douketis, F. Spencer, S. Schulman, 2016, Journal of thrombosis and haemostasis : JTH.

The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Duration of Anticoagulation Study Group.

S. Schulman, 1999, Wiener medizinische Wochenschrift.

Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Narrative Review

S. Schulman, Siavash Piran, 2019, Seminars in Thrombosis and Hemostasis.

Venous thromboembolism in older adults: A community-based study.

J. Gurwitz, J. Saczynski, R. Goldberg, 2014, The American journal of medicine.

Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial

J. Eikelboom, S. Schulman, C. Kearon, 2014, Journal of thrombosis and haemostasis : JTH.

Pharmacologic tools to reduce bleeding in surgery.

S. Schulman, 2012, Hematology. American Society of Hematology. Education Program.

Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure

J. Douketis, J. Eikelboom, M. Blostein, 2016, Journal of thrombosis and haemostasis : JTH.

Experiences of a low-intensity anticoagulation regimen for extended secondary prevention of venous thromboembolism.

P. Svensson, S. Schulman, Anna Södermark, 2002, The hematology journal : the official journal of the European Haematology Association.

Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art

A. Maraveyas, B. Cosmi, A. Falanga, 2022, AntiCancer Research.

Experiences with continuous infusion of recombinant activated factor VII.

M. Morfini, J. Goudemand, C. Négrier, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Treatment of bleeding complications in patients on anticoagulant therapy.

S. Schulman, Siavash Piran, 2019, Blood.

Practice Guidelines Chest Physicians Evidence-Based Clinical Thrombosis, 9th ed: American College of Antithrombotic Therapy and Prevention of Prevention of VTE in Nonsurgical Patients :

D. Cook, E. Akl, M. Cushman, 2012 .

Treatment and Prevention of Heparin-Induced Thrombocytopenia Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

A. Dans, S. Schulman, M. Crowther, 2011 .

The duration of oral anticoagulation after deep vein thrombosis. A randomized study.

S. Schulman, A. Juhlin-Dannfelt, D. Lockner, 2009, Acta medica Scandinavica.

Relationship Between Thromboembolic Complications and Intensity of Treatment During Long-Term Prophylaxis with Oral Anticoagulants Following DVT

S. Schulman, D. Lockner, 1985, Thrombosis and Haemostasis.

Effect of a simple two‐step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study

J. Eikelboom, S. Schulman, K. Meijer, 2010, Journal of thrombosis and haemostasis : JTH.

Arterial Thrombosis in Patients with Antiphospholipid Syndrome: A Review and Meta-Analysis

S. Schulman, J. Aibar, 2021, Seminars in Thrombosis and Hemostasis.

Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10

W. Ageno, S. Kahn, P. Wells, 2010, Thrombosis and Haemostasis.

Quality of oral anticoagulant control and treatment in Sweden

S. Schulman, 1994, Journal of internal medicine.

Systematic Review of Observational Studies Assessing Bleeding Risk in Patients with Atrial Fibrillation Not Using Anticoagulants

G. Guyatt, J. Eikelboom, F. Spencer, 2014, PloS one.

Systematic Review/Meta-analysis Safety and Efficacy of Dabigatran Compared With Warfarin for Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-analysis

J. Healey, C. Morillo, S. Schulman, 2013 .

Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy

S. Connolly, J. Eikelboom, S. Cuddy, 2012, Thrombosis and Haemostasis.

Extension of anticoagulation after venous thromboembolism

S. Schulman, S. Schulman, 2008, Hämostaseologie.

Is 3 months the optimum duration of anticoagulation therapy for deep vein thrombosis and pulmonary embolism?

S. Schulman, 2007, Nature Clinical Practice Cardiovascular Medicine.

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study

J. Douketis, S. Schulman, J. Caprini, 2020, Journal of the American Heart Association.

Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines

J. Douketis, S. Syed, S. Schulman, 2015, Regional Anesthesia & Pain Medicine.

Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity

B. Wiman, S. Schulman, A. Ågren, 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Safety and Efficacy of Continuous Infusion of a Combined Factor VIII – von Willebrand Factor (vWF) Concentrate (Haemate-P™) in Patients with von Willebrand Disease

S. Schulman, G. Kenet, A. Lubetsky, 1999, Thrombosis and Haemostasis.

A randomized, controlled, dose‐guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I

S. Schulman, L. Welin, H. Eriksson, 2003, Journal of thrombosis and haemostasis : JTH.

How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy.

S. Schulman, 2017, Blood.

Optimal timing of vitamin K antagonist resumption after upper gastrointestinal bleeding

M. Bottai, S. Schulman, M. Holmström, 2016, Thrombosis and Haemostasis.

Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.

S. Schulman, H. Eriksson, K. Wåhlander, 2003, The New England journal of medicine.

Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

S. Schulman, S. Kaatz, A. Spyropoulos, 2015, Journal of thrombosis and haemostasis : JTH.

Thrombosis in inherited factor VII deficiency

J. Astermark, G. Mariani, F. Bernardi, 2003, Journal of thrombosis and haemostasis : JTH.

Thrombotic Complications after Substitution with a FVII Concentrate

S. Schulman, P. Lindmarker, H. Johnsson, 1991, Thrombosis and Haemostasis.

Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight heparin in patients with mechanical heart valves

S. Schulman, E. Mattsson, M. Holmström, 2015, Journal of Thrombosis and Thrombolysis.

Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach

J. Halperin, A. Turpie, C. Kessler, 2013, Journal of thrombosis and haemostasis : JTH.

Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban

C. Weiss, S. Schulman, J. Harenberg, 2012, Journal of thrombosis and haemostasis : JTH.

Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial

S. Kahn, D. Anderson, P. Wells, 2021, BMJ.

Effect of Direct Oral Anticoagulant, Patient, and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation Study

J. Douketis, S. Schulman, N. Clark, 2020, TH open : companion journal to thrombosis and haemostasis.

Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients.

M. Blombäck, S. Schulman, L. Grip, 1991, European heart journal.

Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer

S. Goldhaber, M. Feuring, S. Schulman, 2015, Thrombosis and Haemostasis.

Bleeding events with dabigatran or warfarin in patients with venous thromboembolism

S. Goldhaber, M. Feuring, S. Schulman, 2016, Thrombosis and Haemostasis.

Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

S. Goldhaber, M. Feuring, S. Schulman, 2013 .

Studies on the medical treatment of deep vein thrombosis.

S. Schulman, 2009, Acta medica Scandinavica. Supplementum.

ISTH guidelines for antithrombotic treatment in COVID‐19

C. Samama, A. Falanga, J. Thachil, 2022, Journal of Thrombosis and Haemostasis.

Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH

J. Douketis, R. Lopes, J. Connors, 2022, Journal of Thrombosis and Haemostasis.

Influence of changes in lifestyle on fibrinolytic parameters and recurrence rate in patients with venous thromboembolism

S. Schulman, P. Lindmarker, H. Johnsson, 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Activated prothrombin complex concentrate for dabigatran‐associated bleeding

B. Ritchie, S. Schulman, S. Nahirniak, 2014, British journal of haematology.

Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism

S. Goldhaber, S. Schulman, David Baanstra, 2013 .

New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism

S. Schulman, M. Ogren, Mats Ögren, 2006, Thrombosis and Haemostasis.

RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate

G. Raskob, D. Singer, W. Ageno, 2016, Thrombosis and Haemostasis.

Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism

S. Schulman, F. Bacchus, 2015, Arteriosclerosis, thrombosis, and vascular biology.

Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients

S. Kahn, P. Sandset, S. Schulman, 2021, Journal of thrombosis and haemostasis : JTH.

Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study

D. Singer, W. Ageno, K. Chee, 2020, Journal of Thrombosis and Thrombolysis.

Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time.

J. Douketis, S. Schulman, C. Dubé, 2018, Thrombosis Research.

Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials

S. Schulman, N. Goldenberg, C. Tarango, 2018, Expert review of hematology.

Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II

S. Goldhaber, M. Feuring, S. Schulman, 2017, Thrombosis and Haemostasis.

Direct Oral Anticoagulants in the Real World

S. Schulman, M. Pai, M. Salib, 2017, The Canadian journal of nursing research = Revue canadienne de recherche en sciences infirmieres.

Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER™ II, and RE-MEDY™

S. Goldhaber, M. Feuring, S. Schulman, 2017, Journal of Thrombosis and Thrombolysis.

DIRECT ORAL ANTICOAGULANTS COMPARED WITH VITAMIN K ANTAGONISTS FOR ACUTE SYMPTOMATIC VENOUS THROMBOEMBOLISM: CLINICAL EVIDENCE FROM PHASE 3 TRIALS

H. Büller, S. Middeldorp, S. Schulman, 2017 .

Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™

S. Goldhaber, M. Feuring, S. Schulman, 2016, Vascular medicine.

THROMBOSIS AND HEMOSTASIS Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials

H. Büller, S. Middeldorp, S. Schulman, 2014 .

Adherence to anticoagulant treatment with dabigatran in a real‐world setting

J. Eikelboom, S. Schulman, B. Shortt, 2013, Journal of thrombosis and haemostasis : JTH.

Treatment of venous thromboembolism with dabigatran

S. Schulman, 2012, Current opinion in pulmonary medicine.

The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses

S. Schulman, A. Majeed, 2012, Seminars in Thrombosis & Hemostasis.

Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study

D. Singer, W. Ageno, K. Chee, 2021, Seminars in Thrombosis and Hemostasis.

Fondaparinux treatment of acute heparin‐induced thrombocytopenia confirmed by the serotonin‐release assay: a 30‐month, 16‐patient case series

J. Eikelboom, S. Schulman, M. Pai, 2011, Journal of thrombosis and haemostasis : JTH.

Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post‐thrombotic syndrome

M. Cushman, S. Kahn, M. Rodger, 2015, Journal of thrombosis and haemostasis : JTH.

Inflammation Markers and Their Trajectories after Deep Vein Thrombosis in relation to Risk of Postthrombotic Syndrome INFLAMMATION BIOMARKERS IN PTS

M. Cushman, S. Kahn, S. Solymoss, 2014 .

Optimal Duration of Anticoagulant Therapy

S. Schulman, 2013, Seminars in Thrombosis & Hemostasis.

Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial.

J. Douketis, J. Healey, C. Morillo, 2014, Thrombosis research.

Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene

J. Astermark, S. Schulman, A. Batorova, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Decreasing warfarin sensitivity during the first three months after heart valve surgery: implications for dosing.

S. Schulman, K. Meijer, Y.-K. Kim, 2010, Thrombosis research.

Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study

S. Schulman, Siavash Piran, Caroline Gabriel, 2018, Journal of Thrombosis and Thrombolysis.

The Role of Ximelagatran in the Treatment of Venous Thromboembolism

S. Schulman, 2005, Pathophysiology of Haemostasis and Thrombosis.

Prevention of the post thrombotic syndrome with anticoagulation: a narrative review

S. Kahn, S. Schulman, I. Makedonov, 2021, Thrombosis and Haemostasis.

Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial

S. Kahn, S. Schulman, D. T. Nguyen, 2020, Seminars in Thrombosis and Hemostasis.

Long‐term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d‐dimer results; A cohort study

J. Douketis, S. Stevens, Vinay Shah, 2019, Journal of thrombosis and haemostasis : JTH.

D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.

J. Douketis, S. Stevens, C. Kessler, 2015, Annals of internal medicine.

Distal deep vein thrombosis--a benign disease?

S. Schulman, 2014, Thrombosis research.

Thromboprophylaxis in Medical Patients – Why Not For All?

S. Schulman, Sam Schulman, 2006, Pathophysiology of Haemostasis and Thrombosis.

Anticoagulant treatment of COVID-19 as early as possible - Sulodexide and perspectives.

S. Schulman, J. Harenberg, 2021, Thrombosis and haemostasis.

Secondary prevention of venous thromboembolism

J. Douketis, S. Schulman, 2013, BMJ : British Medical Journal.

Extended anticoagulation in venous thromboembolism.

S. Schulman, 2013, The New England journal of medicine.

A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)

S. Goldhaber, S. Schulman, S. Schellong, 2011 .

Prolonged Bleeding After Surgery

S. Schulman, 2014 .

Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers

S. Schulman, M. Pai, Siavash Piran, 2017, Journal of Thrombosis and Thrombolysis.

Accumulating data on rivaroxaban for venous thromboembolism in clinical practice

S. Schulman, 2017, Thrombosis and Haemostasis.

Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II.

S. Goldhaber, M. Feuring, S. Schulman, 2017, Thrombosis and haemostasis.

Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism

S. Goldhaber, M. Feuring, S. Schulman, 2014 .

The pathogenesis and treatment of hemolytic uremic syndrome.

S. Schulman, K. Meyers, B. Kaplan, 1998, Journal of the American Society of Nephrology : JASN.

Perioperative Management of DabigatranCLINICAL PERSPECTIVE

J. Douketis, S. Solymoss, M. Blostein, 2015 .

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

Yutao Guo, Harlan M. Krumholz, Yu Hu, 2020, Journal of the American College of Cardiology.

Cyclosporine Therapy for Acquired Factor VIII Inhibitor in a Patient with Systemic Lupus Erythematosus

S. Schulman, U. Martinowitz, D. Varon, 1996, Thrombosis and Haemostasis.

Increased fetal loss in women with heritable thrombophilia

F. Rosendaal, C. Legnani, M. Makris, 1996, The Lancet.

Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials.

P. Kyrle, J. Cox Gill, J. Di Paola, 2013, Blood transfusion = Trasfusione del sangue.

Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations

R. Tait, S. Schulman, A. Mumford, 2008, Thrombosis and Haemostasis.

Haemorrhagic and thromboembolic complications versus intensity of treatment of venous thromboembolism with oral anticoagulants.

J. Jansson, S. Schulman, J. Brohult, 2009, Acta medica Scandinavica.

Treatment of Venous Thromboembolism in Patients with Congenital Deficiency of Antithrombin III

S. Schulman, L. Tengborn, 1992, Thrombosis and Haemostasis.

Reply to Dr Lessire et al

J. Douketis, S. Syed, S. Schulman, 2016, Regional Anesthesia & Pain Medicine.

Recurrence after stopping anticoagulants in women with combined oral contraceptive‐associated venous thromboembolism: A systematic review and meta‐analysis

J. Douketis, M. Cushman, M. Marcucci, 2022, British journal of haematology.

Adherence to apixaban for extended thromboprophylaxis after major abdominal or pelvic surgery for cancer: A prospective cohort study

K. Kahnamoui, S. Schulman, P. Gross, 2022, Journal of surgical oncology.

Optimal reversal of vitamin K antagonists.

S. Schulman, 2007, Thrombosis research.

Recent Advances in Thrombosis and Hemostasis – Part III

S. Schulman, 2018, Seminars in Thrombosis and Hemostasis.

The accuracy of the International Normalized Ratio and the American College of Chest Physicians recommendations on the use of vitamin K to reverse over‐anticoagulation: a rebuttal

A. Holbrook, S. Schulman, M. Crowther, 2013, Journal of thrombosis and haemostasis : JTH.

Management and Outcomes of Major Bleeding On Dabigatran or Warfarin

S. Yusuf, M. Ezekowitz, S. Connolly, 2012 .

Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin".

S. Yusuf, M. Ezekowitz, S. Connolly, 2014, Circulation.

Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation

W. Ageno, M. Di Nisio, E. Porreca, 2021, Journal of thrombosis and haemostasis : JTH.

Clinical factors influencing the sensitivity to warfarin when restarted after surgery

J. Eikelboom, S. Schulman, M. Zondag, 2008, Journal of internal medicine.

Interaction of ibuprofen and warfarin on primary haemostasis.

S. Schulman, K. Henriksson, Sam Schulman, 1989, British journal of rheumatology.

Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis

Gordon H. Guyatt, Michael J. Kovacs, Daniel M. Witt, 2011 .

A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery.

S. Schulman, K. Meijer, Yang-Ki Kim, 2010, Thrombosis and haemostasis.

Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range.

S. Schulman, L. Rudd-Scott, A. Melinyshyn, 2010, Thrombosis research.

Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism.

J. Douketis, S. Stevens, C. Kessler, 2018, Blood.

D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment.

J. Douketis, S. Stevens, C. Kessler, 2016, Thrombosis research.

Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry

W. Ageno, F. Dentali, E. Grandone, 2012, Seminars in Thrombosis & Hemostasis.

Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry

W. Ageno, F. Dentali, E. Grandone, 2012 .

A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery

S. Schulman, A. Majeed, 2011, Drug safety.

Other Uses of LMWHs – Miscellaneous

Paolo Prandoni, Mark Levine, Frederick R. Rickles, 1998, Pathophysiology of Haemostasis and Thrombosis.

Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study Designer D-Dimer Deep vein thrombosis (4D) Study

F. D’Aragon, S. Kahn, M. Afilalo, 2022 .

Positive Predictive Value of Progressively Elevated D-Dimer Levels in Patients with a Suspected First Deep Vein Thrombosis.

J. Douketis, S. Schulman, J. Julian, 2012 .

Bacchus and Schulman New Anticoagulants for Venous Thrombosis 7 of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism

S. Schulman, J. Weitz, F. Bacchus, 2022 .

Recent Advances in Thrombosis and Hemostasis: Part VI

S. Schulman, 2020, Seminars in Thrombosis and Hemostasis.

Flavonoid Fraction for the Treatment of Post- Thrombotic Syndrome: protocol of a randomised controlled trial

S. Kahn, S. Schulman, G. Gal, 2021 .

A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant

J. Douketis, S. Syed, S. Schulman, 2020, Research and practice in thrombosis and haemostasis.

Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial

Christina Holcroft, Mira Johri, Stan Shapiro, 2014, The Lancet.

Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial

T. Ortel, P. Wells, M. Rodger, 2013 .

Long-Term Prophylaxis in Venous Thromboembolism: LMWH or Oral Anticoagulation?

S. Schulman, 1998, Pathophysiology of Haemostasis and Thrombosis.

COVID-19, hemostasis disorders and risk of thrombotic complications

J. Gris, E. Grandone, S. Schulman, 2020, Annals of the Russian academy of medical sciences.

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients

Á. Soriano, S. Schulman, P. Castro, 2021, Medicina Intensiva.

Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Gordon H Guyatt, Elie A Akl, Maarten G Lansberg, 2012, Chest.

The Significance of Hypofibrinolysis for the Risk of Recurrence of Venous Thromboembolism

B. Wiman, S. Schulman, 1996, Thrombosis and Haemostasis.

The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin

M. Kovacs, S. Schulman, M. Crowther, 2016, Thrombosis and Haemostasis.

Platelet-leukocyte aggregation under shear stress: Differential involvement of selectins and integrins

P. Hjemdahl, S. Schulman, N. Savion, 2003, Thrombosis and Haemostasis.

Novel anticoagulant agents: introduction

S. Schulman, 2003, Journal of internal medicine.

A Comparative Randomized Trial of Low-Dose Versus High-Dose Streptokinase in Deep Vein Thrombosis of the Thigh

S. Schulman, G. Bratt, S. Granqvist, 1984, Thrombosis and Haemostasis.

Hip resurfacing: a complex challenge for device regulation

S. Schulman, J. Julian, S. Parpia, 2012 .

Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings

J. Halperin, N. Stence, P. Steg, 2015, Journal of thrombosis and haemostasis : JTH.

Safety, efficacy and lessons from continuous infusion with rFVIIa

C. Kessler, S. Schulman, U. Martinowitz, 1998 .

Continuous infusion instead of bolus injections of factor concentrate?

S. Schulman, U. Martinowitz, S. Schulman, 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

Thrombolysis and fibrinolytic parameters during heparin treatment of deep vein thrombosis.

B. Wiman, S. Schulman, S. Granqvist, 1985, Thrombosis research.

Thrombophilia and location of venous thromboembolism

S. Schulman, 2007, Journal of thrombosis and haemostasis : JTH.

Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Elie A Akl, Mary Cushman, Wendy Lim, 2013 .

Less menorrhagia for women with VTE.

S. Schulman, 2016, Blood.

Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

R. Pfeiffer, M. Björkholm, S. Schulman, 2014, Journal of thrombosis and haemostasis : JTH.

Is the network meta-analysis (NETMA) bringing us closer to the truth? Insights from recent antithrombotic drug data

S. Schulman, 2012, Thrombosis and Haemostasis.

Thrombophilic polymorphism – a short‐term or long‐term risk for recurrence?

S. Schulman, P. Lindmarker, 2008, Journal of thrombosis and haemostasis : JTH.

Moderate Renal Impairment and Risk of Bleeding With Anticoagulation

R. Beyth, M. Levine, S. Schulman, 2017 .

Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials

J. Douketis, A. Maraveyas, A. Falanga, 2022, Journal of clinical medicine.

Splanchnic vein thrombosis: what are the long-term risks?

S. Schulman, 2018, The Lancet. Haematology.

Can fondaparinux safely prevent the occurrence of venous thromboembolism in acutely ill medical patients?

S. Schulman, 2006, Nature Clinical Practice Cardiovascular Medicine.

Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation

S. Schulman, K. Meijer, N. Khorsand, 2021, Journal of thrombosis and haemostasis : JTH.

Real‐world variability in dabigatran levels in patients with atrial fibrillation

J. Douketis, J. Hirsh, J. Eikelboom, 2015, Journal of thrombosis and haemostasis : JTH.

Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant

J. Douketis, Vinay Shah, S. Solymoss, 2018, Blood.

More on: vitamin K antagonists and cancer

S. Schulman, 2008 .

Recombinant FVIIa in children with liver disease.

S. Schulman, A. Németh, P. Petrini, 2005, Thrombosis research.

Appropriateness of Apixaban Dosing to Prevent Stroke in Patients with Atrial Fibrillation: A Pilot Study.

S. Schulman, J. Pickering, Stephanie Carlin, 2016, The Canadian journal of hospital pharmacy.

Coagulation factor concentrates by continuous infusion.

S. Schulman, U. Martinowitz, 1997, Transfusion medicine reviews.

Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group.

S. Schulman, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

Feasibility of Using Recombinant Factor VIIa in Continuous Infusion

S. Schulman, H. Horoszowski, U. Martinowitz, 1996, Thrombosis and Haemostasis.

Is venous thromboembolism a preventable cause of death?

S. Schulman, 2020, The Lancet. Haematology.

Association of Venous Thromboembolism With Hormonal Contraception and Thrombophilic Genotypes

J. Odeberg, S. Schulman, I. Persson, 2014, Obstetrics and gynecology.

Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion.

J. Healey, J. Eikelboom, S. Schulman, 2013, Thrombosis research.

Anticoagulant therapy for splanchnic vein thrombosis

W. Ageno, M. Di Nisio, S. Schulman, 2020, Journal of thrombosis and haemostasis : JTH.

2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association.

J. Mocco, S. Greenberg, W. Ziai, 2022, Stroke.

Effect of Reversal of Neuromuscular Blockade with Sugammadex versus Usual Care on Bleeding Risk in a Randomized Study of Surgical Patients

H. Fennema, A. Szegedi, M. Blobner, 2014, Anesthesiology.

Recent Advances in Thrombosis and Hemostasis-Part VIII.

S. Schulman, 2022, Seminars in thrombosis and hemostasis.

High Factor VIII Levels and Recurrent Thromboembolism in Patients with and without Inflammatory Bowel Disease: A Retrospective Comparative Study

S. Schulman, G. E. Eagle, 2022, TH open : companion journal to thrombosis and haemostasis.

Getting intimate with the venous thrombus

S. Schulman, S. Schulman, 2009, Journal of thrombosis and haemostasis : JTH.

Recent Advances in Thrombosis and Hemostasis—Part V

S. Schulman, 2019, Seminars in Thrombosis and Hemostasis.

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients

Á. Soriano, S. Schulman, P. Castro, 2021, Medicina Intensiva (English Edition).

DDAVP--the multipotent drug in patients with coagulopathies.

S. Schulman, 1991, Transfusion medicine reviews.

Recent Advances in Thrombosis and Hemostasis—Part IV

S. Schulman, 2019, Seminars in Thrombosis and Hemostasis.

Arterial Thrombotic Events in Hospitalized COVID-19 Patients: A Short Review and Meta-Analysis

S. Schulman, M. Candeloro, 2022, Seminars in Thrombosis and Hemostasis.

Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials

Giancarlo Agnelli, Florent Boutitie, G. Raskob, 2011, BMJ : British Medical Journal.

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism

Vinay Shah, S. Kahn, D. Anderson, 2022, Blood advances.

Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis

W. Ageno, F. Dentali, I. Martinelli, 2018, Clinical and Translational Gastroenterology.

“ISTH guidelines for antithrombotic treatment in COVID‐19”: Reply

R. Zarychanski, S. Schulman, M. Sholzberg, 2022, Journal of Thrombosis and Haemostasis.

Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant.

J. Douketis, Vinay Shah, S. Solymoss, 2019, JAMA internal medicine.

Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure

J. Douketis, S. Schulman, A. Spyropoulos, 2022, Journal of thrombosis and haemostasis : JTH.

Epidural Catheter Use and Further Issues in Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant-Reply.

J. Douketis, S. Schulman, A. Spyropoulos, 2020, JAMA internal medicine.

Modification of von Willebrand Disease after Liver Transplantation

S. Schulman, B. Ericzon, L. Eleborg, 2001, Thrombosis and Haemostasis.

Antibodies against hepatitis C in a population of Swedish haemophiliacs and heterosexual partners.

S. Schulman, L. Grillner, 1990, Scandinavian journal of infectious diseases.

Definition of pulmonary embolism‐related death and classification of the cause of death in venous thromboembolism studies: Communication from the SSC of the ISTH

H. Büller, N. Langlois, S. Schulman, 2020, Journal of thrombosis and haemostasis : JTH.

Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure.

J. Douketis, S. Syed, S. Schulman, 2020, Blood advances.

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

J. Douketis, S. Schulman, J. Caprini, 2019, Blood.

Pulmonary hypertension in hemophilia.

S. Blomqvist, S. Schulman, H. Johnsson, 1988, Annals of internal medicine.

Role of Fibrin Sealants in Surgical Procedures on Patients With Hemostatic Disorders

S. Schulman, H. Horoszowski, U. Martinowitz, 1996, Clinical orthopaedics and related research.

Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study

J. Eikelboom, S. Schulman, N. Chan, 2019, Blood.

Duration of anticoagulants in acute or recurrent venous thromboembolism

S. Schulman, 2000, Current opinion in pulmonary medicine.

Hypercoagulability preceding cancer

S. Schulman, 2005, Journal of thrombosis and haemostasis : JTH.

Practice Guidelines Chest Physicians Evidence-Based Clinical Thrombosis, 9th ed: American College of Antithrombotic Therapy and Prevention of Heparin-Induced Thrombocytopenia : Treatment and Prevention of

S. Schulman, M. Crowther, R. Bona, 2012 .

Development of a standardized definition of pulmonary embolism‐related death: A cross‐sectional survey of international thrombosis experts

H. Büller, N. Langlois, S. Schulman, 2020, Journal of thrombosis and haemostasis : JTH.

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

O. Linder, S. Schulman, J. Boberg, 1997, The New England journal of medicine.

Author’s reply

S. Schulman, 2001 .

The Effectiveness of Desmopressin in Patients with Disorders of Primary Haemostasis

S. Schulman, 1993 .

DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects.

M. Blombäck, S. Schulman, N. Egberg, 1987, Thrombosis research.

[Desmopressin--an effective agent in many hemorrhagic disorders].

S. Lethagen, S. Schulman, L. Tengborn, 1992, Lakartidningen.

Heparin, DDAVP and the Bleeding Time

S. Schulman, H. Johnsson, 1991, Thrombosis and Haemostasis.

Recommendations on biosimilar low‐molecular‐weight heparins

D. Bergqvist, S. Schulman, P. Mismetti, 2009, Journal of thrombosis and haemostasis : JTH.

Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery

S. Schulman, B. White, R. Wallensten, 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized

J. Astermark, R. Ljung, S. Schulman, 1999, British journal of haematology.

Evidence-Based Management of Anticoagulant Therapy

Jason C. Fish, G. Guyatt, A. Holbrook, 2012 .

On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome

B. Lindgren, S. Lethagen, A. Lindgren, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Validation of a composite score for clinical severity of hemophilia

M. Blombäck, J. Odeberg, S. Schulman, 2008, Journal of thrombosis and haemostasis : JTH.

Confusion around the official classification of arthropathy

S. Schulman, A. Eelde, Sam Schulman, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Fibrin Sealant in Surgery of Patients with a Hemorrhagic Diathesis

S. Schulman, U. Martinowitz, 1995, Thrombosis and Haemostasis.

Adjusted dose continuous infusion of factor VIII in patients with haemophilia A

S. Schulman, U. Martinowitz, M. Heim, 1992, British journal of haematology.

Costs of on‐demand and prophylactic treatment for severe haemophilia in Norway and Sweden

B. Lindgren, S. Lethagen, S. Schulman, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES

G. Guyatt, D. Cook, M. McDonagh, 2012 .

Multiple Joint Procedures in a Single Operative Session on Hemophilic Patients

S. Schulman, H. Horoszowski, U. Martinowitz, 1996, Clinical orthopaedics and related research.

Recombinant factor VIIa in multiple surgery.

S. Schulman, K. Alberts, M. Lindstedt, 1994, Thrombosis and haemostasis.

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients

S. Schulman, C. Kearon, S. SCHULMAN, 2005, Journal of thrombosis and haemostasis : JTH.

The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors

M. Morfini, S. Schulman, 2001 .

Continuous intravenous infusion of a plasma‐derived factor IX concentrate (Mononine®) in haemophilia B

C. Leissinger, C. Négrier, S. Schulman, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Continuous infusion

S. Schulman, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

The feasibility of using concentrates containing factor IX for continuous infusion

S. Schulman, U. Martinowitz, D. Varon, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical Trials of Recombinant Factor VIII

P. Mannucci, C. Kessler, H. Kingdon, 1991 .

Home therapy with continuous infusion of factor VIII after minor surgery or serious haemorrhage

S. Schulman, D. Bashari, U. Martinowitz, 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetic properties of two factor VIII concentrates with single and double viral inactivation

S. Schulman, H. Brackmann, U. Martinowitz, 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience.

S. Schulman, U. Martinowitz, D. Varon, 1994, Thrombosis and haemostasis.

Stability of factor VIII concentrates after reconstitution

S. Schulman, U. Martinowitz, S. Gitel, 1994, American journal of hematology.

The fixed flexed and subluxed knee in the haemophilic child: what should be done?

M. Heim, S. Schulman, H. Horoszowski, 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

Multifocal pseudotumour in a single limb

S. Schulman, H. Horoszowski, U. Martinowitz, 1997, Haemophilia.

Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate.

B. Wiman, S. Schulman, A. Ågren, 2007, Thrombosis research.

An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency

S. Schulman, G. Németh, Sam Schulman, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

A molecular genetic study of factor XI deficiency.

D. Cooper, J. Hancock, V. Kakkar, 1991, Blood.

Oral surgery in patients with hereditary bleeding disorders. A survey of treatment in the Stockholm area (1974-1985).

M. Blombäck, S. Schulman, N. Egberg, 1989, International journal of oral and maxillofacial surgery.

Factors and inhibitors of blood coagulation and fibrinolysis in acute nonlymphoblastic leukaemia.

M. Blombäck, S. Schulman, G. Bratt, 2009, Scandinavian journal of haematology.

A therapeutic alternative for haemophiliacs with inhibitors

S. Schulman, 1992, Acta paediatrica.

Bile acids and coagulation factors: paradoxical association in children with chronic liver disease

S. Schulman, A. Németh, P. Petrini, 2013, European journal of gastroenterology & hepatology.

Partial expression of GP Ib measured by flow cytometry in two patients with Bernard-Soulier syndrome.

T. Lindahl, A. Larsson, J. Lundahl, 1994, Thrombosis research.

Direct Oral Anticoagulant‐ or Warfarin‐Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study

T. Gomes, M. Mamdani, A. Holbrook, 2017, Chest.

Characteristics of septic arthritis in human immunodeficiency virus-infected haemophiliacs versus other risk groups.

S. Schulman, U. Martinowitz, D. Varon, 1999, Rheumatology.

Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B.

S. Schulman, U. Martinowitz, 1995, Acta haematologica.

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Yngve Falck-Ytter, Clifford W Colwell, Stephen G Pauker, 2012, Chest.

Minimizing factor requirements for surgery without increased risk

S. Schulman, R. Wallensten, J. Loogna, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Continuous infusion of B‐domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience

G. Auerswald, C. Négrier, S. Schulman, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Major surgery seems not to influence HIV disease progression in haemophilia patients

Samuel M. Schulman, J. Astermark, S. Lethagen, 1998, British journal of haematology.

Joint Surgery in Patients with Inhibitors

S. Schulman, 2007 .

Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery

S. Schulman, B. White, R. Wallensten, 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

Review of pumps for continuous infusion of coagulation factor concentrates: what are the options?

S. Schulman, U. Martinowitz, 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII

S. Schulman, G. Tjønnfjord, G. Kenet, 2005, Thrombosis and Haemostasis.

Acute effects with reference to thrombogenicity and liver toxicity after injection of different coagulation factor concentrates.

B. Wiman, S. Schulman, H. Johnsson, 1989, Haemostasis.

Haemophilia in the 1990s: Report of a Joint Meeting of the World Health Organization and World Federation of Hemophilia

P. Mannucci, A. Chuansumrit, D. Brettler, 1991, Vox sanguinis.

Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis

G. Guyatt, E. Akl, J. Eikelboom, 2014, BMJ Open.

HIV infection in a defined population of Swedish haemophiliacs.

M. Blombäck, S. Schulman, N. Egberg, 1987, Scandinavian journal of infectious diseases.

Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs.

S. Schulman, K. Meijer, 2008, Seminars in thrombosis and hemostasis.

Cervical artery dissection: pathology, epidemiology and management.

S. Schulman, Yang-Ki Kim, 2009, Thrombosis research.

Recent Advances in Thrombosis and Hemostasis – Part I

M. Islam, S. Schulman, 2016, Seminars in Thrombosis and Hemostasis.

Recent Advances in Thrombosis and Hemostasis—Part II

M. Islam, S. Schulman, 2017, Seminars in Thrombosis and Hemostasis.

Berzelius Symposium 93: International Conference on Thrombosis and Embolism

M. Islam, S. Schulman, 2017, Seminars in Thrombosis and Hemostasis.

Lemierre syndrome – treat with antibiotics, anticoagulants or both?

S. Schulman, 2020, Journal of internal medicine.

Effect of perioperative benzodiazepine use on intraoperative awareness and postoperative delirium: a systematic review and meta-analysis of randomised controlled trials and observational studies.

C. Mazer, F. D’Aragon, E. Belley‐Cote, 2023, British journal of anaesthesia.

Potential antidotes for reversal of old and new oral anticoagulants.

S. Schulman, D. Suryanarayan, 2014, Thrombosis research.

Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty: Results of Separate Pooled Analyses of Phase III Multicenter Randomized Trials

M. Huisman, S. Schulman, D. Quinlan, 2010, Circulation. Cardiovascular quality and outcomes.

Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients?

S. Schulman, N. Egberg, J. Ungerstedt, 2002, Blood.

Total thrombin‐activatable fibrinolysis inhibitor (TAFI) antigen and pro‐TAFI in patients with haemophilia A

M. Blombäck, S. Schulman, J. Antovic, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Intensive Initial Oral Anticoagulation and Shorter Heparin Treatment in Deep Vein Thrombosis

M. Blombäck, S. Schulman, D. Lockner, 1984, Thrombosis and Haemostasis.

Variability of clinical manifestation of factor VII-deficiency in homozygous and heterozygous subjects of the European F7 gene mutation A294V

J. Astermark, S. Schulman, K. Wulff, 2008, Haematologica.

Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention

M. Margaglione, W. Ageno, J. Eikelboom, 2009, American journal of hematology.

Effects of factor VIII concentrates on the immune system in hemophilic patients

S. Schulman, 1991, Annals of Hematology.

Immunoglobulin levels in haemophiliacs at HIV seroconversion and during follow up

M. Blombäck, S. Schulman, N. Egberg, 1987, Infection.

New-Onset Atrial Fibrillation in Sepsis: A Narrative Review

S. Schulman, J. Aibar, 2020, Seminars in Thrombosis and Hemostasis.

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

D. Singer, G. Lip, A. Go, 2012, Chest.

New oral anticoagulant agents – general features and outcomes in subsets of patients

S. Schulman, Sam Schulman, 2014, Thrombosis and Haemostasis.

Advantages and limitations of the new anticoagulants

S. Schulman, 2014, Journal of internal medicine.

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

Mehrad Amin Eskandari, J. F. Tinto, A. Capucci, 2018, Indian heart journal.

Are NSAIDs Double Trouble?

S. Schulman, J. Aisenberg, 2018, Journal of the American College of Cardiology.

Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation

P. Heuschmann, J. Martí-Fàbregas, A. Biffi, 2017, Neurology.

Is the network meta-analysis ( NETMA ) bringing us closer to the truth ?

S. Schulman, 2017 .

Advances in the management of venous thromboembolism.

S. Schulman, 2012, Best practice & research. Clinical haematology.

37 – Antithrombotic Therapy

J. Hirsh, S. Schulman, 2012 .

Care of Patients Receiving Long-Term Anticoagulant Therapy

S. Schulman, 2003 .

Dabigatran Etexilate: Future Directions in Anticoagulant Treatment

S. Schulman, P. Reilly, 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Bleeding Risk in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Systematic Review and Meta‐Analysis

G. Guyatt, J. Eikelboom, S. Schulman, 2013, Clinical pharmacology and therapeutics.

The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale

J. Douketis, F. Dentali, Vinay Shah, 2017, Thrombosis and Haemostasis.

Tossing a coin or using common sense

S. Schulman, 2013, Journal of thrombosis and haemostasis : JTH.

Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: no.

S. Schulman, 2011, Stroke.

Optimal Timing of Resumption of Warfarin After Intracranial Hemorrhage

S. Schulman, R. Roberts, M. Holmström, 2010, Stroke.

Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin

S. Yusuf, M. Ezekowitz, S. Connolly, 2013, Circulation.

Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects*

S. Schulman, L. Nyman, S. Björck, 2006, Current medical research and opinion.

Transmission of HIV infection to heterosexual partners but not to household contacts of seropositive haemophiliacs.

M. Blombäck, S. Schulman, E. Berntorp, 1986, Scandinavian journal of infectious diseases.

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

E. Svenungsson, S. Schulman, S. Granqvist, 1998, The American journal of medicine.

Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus.

J. Giesecke, Gianpaolo Scalia-Tomba, S. Schulman, 1988, BMJ.

Hepatitis C virus-infected, HCV-RNA-negative patients with bleeding disorders--relationship to age, HIV and treatment.

S. Schulman, P. Petrini, P. Fahlstadius, 1998, Scandinavian journal of infectious diseases.

Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry.

W. Ageno, F. Dentali, M. Di Nisio, 2015, JAMA internal medicine.

Anticoagulants and their reversal.

S. Schulman, Sam Schulman, Nick R Bijsterveld, 2007, Transfusion medicine reviews.

Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.

U. Mellqvist, R. Pfeiffer, A. Wåhlin, 2009, Blood.

Thrombosis is associated with inferior survival in multiple myeloma

R. Pfeiffer, M. Björkholm, S. Schulman, 2012, Haematologica.

Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis

W. Ageno, A. de Gottardi, M. Di Nisio, 2022, Blood advances.

Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry.

W. Ageno, F. Dentali, P. Verhamme, 2016, The Lancet. Haematology.

Recent Advances in Thrombosis and Hemostasis—Part VII

S. Schulman, 2021, Seminars in Thrombosis and Hemostasis.

Thrombin generation test in children and adolescents with chronic liver disease.

T. Renné, S. Schulman, A. Németh, 2015, Thrombosis research.

An analysis of the approach to management of childhood nephrotic syndrome by pediatric nephrologists.

S. Schulman, B. Kaplan, W. Primack, 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis.

S. Schulman, P. Salzman, S. Schulman, 2001, The Journal of urology.

Incidence and risk factors for acute kidney injury in patients with excessive anticoagulation on warfarin: a retrospective study

S. Schulman, N. Chan, M. Robinson, 2018, Journal of Thrombosis and Thrombolysis.

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

M. Prins, H. Büller, P. Prandoni, 2019, BMJ.

Local venous infusion of streptokinase in DVT.

S. Schulman, D. Lockner, 1984, Thrombosis research.

A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism

Olle Linder, K. Schulman, O. Linder, 1995 .

Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding

F. Spencer, S. Schulman, F. Spencer, 2010, Journal of thrombosis and haemostasis : JTH.

Vitamin K antagonists and cancer: rebuttal

S. Schulman, P. Lindmarker, 2004, Journal of thrombosis and haemostasis : JTH.

Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Jason C. Fish, G. Guyatt, A. Holbrook, 2012 .

Anticoagulants for the Treatment ofVenous Thromboembolism

S. Schulman, 2009 .

Current strategies in prophylaxis and treatment of venous thromboembolism

S. Schulman, 2008, Annals of medicine.

Anticoagulation in venous Thrombosis

S. Schulman, 1996, Journal of the Royal Society of Medicine.

Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th Thrombosis Guidelines : Antithrombotic Antithrombotic Therapy and Prevention of Methodology for the Development of

D. Cook, M. McDonagh, E. Akl, 2012 .

Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta‐analysis

M. Di Nisio, E. Porreca, S. Schulman, 2020, Journal of thrombosis and haemostasis : JTH.

Inhibition of Warfarin Activity by Ribavirin

S. Schulman, 2002, The Annals of pharmacotherapy.

Hypofibrinolytic State in HIV‐1‐Infected Patients Treated With Protease Inhibitor‐Containing Highly Active Antiretroviral Therapy

E. Sandström, S. Schulman, G. Bratt, 2002, Journal of acquired immune deficiency syndromes.

Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review

P. Prandoni, M. Rodger, F. Klok, 2018, European Respiratory Review.

Practice Guidelines Chest Physicians Evidence-Based Clinical Thrombosis, 9th ed: American College of : Antithrombotic Therapy and Prevention of Antithrombotic Therapy for Atrial Fibrillation

D. Singer, G. Lip, J. Halperin, 2012 .

Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis

S. Kahn, M. Rodger, S. Solymoss, 2018, Journal of thrombosis and haemostasis : JTH.

Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

S. Goldhaber, S. Schulman, S. Schellong, 2014, Circulation.

Venous Thromboembolic Diseases: Diagnosis, Management and Thrombophilia Testing: Observations on NICE Guideline [NG158]

S. Schulman, Yu Hu, S. Konstantinides, 2020, Thrombosis and Haemostasis.

[Low molecular weight heparin--a safer anticoagulant in thrombosis and cancer].

S. Schulman, 2004, Lakartidningen.

Oral Vitamin K Versus Placebo to Correct Excessive Anticoagulation in Patients Receiving Warfarin

S. Vesely, W. Ageno, S. Kahn, 2009, Annals of Internal Medicine.

Warfarin Dose Assessment Every 4 Weeks Versus Every 12 Weeks in Patients With Stable International Normalized Ratios

M. Levine, S. Schulman, J. Julian, 2011, Annals of Internal Medicine.

Direct and indirect costs of management of long‐term warfarin therapy in Canada

S. Kahn, D. Anderson, P. Wells, 2010, Journal of thrombosis and haemostasis : JTH.

Treatment of Venous Thromboembolism with New Oral Anticoagulants According to Patient Risk

S. Schulman, 2015, Seminars in Thrombosis & Hemostasis.

Acquired platelet dysfunction may be an aetiologic factor in Heyde's syndrome – normalization of bleeding time after aortic valve replacement

R. Hultcrantz, S. Schulman, M. Olsson, 2002, Journal of internal medicine.

Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism

S. Schulman, 2020, Seminars in Thrombosis and Hemostasis.

Pregnancy, Heparin and Osteoporosis

S. Schulman, Margareta Hellgren-Wångdahl, 2002, Thrombosis and Haemostasis.

When the Rubber Meets the Road: Adherence and Persistence with Non–Vitamin K Antagonist Oral Anticoagulants and Old Oral Anticoagulants in the Real World—A Problem or A Myth ?

S. Schulman, D. Suryanarayan, 2014, Seminars in Thrombosis & Hemostasis.

Molecular genetic analysis of severe protein C deficiency

D. Cooper, V. Kakkar, S. Schulman, 2000, Human Genetics.

Frailty phenotype as a predictor of bleeding and mortality in ambulatory patients receiving direct oral anticoagulants

M. Di Nisio, Nicola Potere, E. Porreca, 2022, Journal of the American Geriatrics Society.

6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII

S. Eichinger, P. Kyrle, S. Schulman, 2009, Annals of Hematology.

Anticoagulant Management and Outcomes in Nontraumatic Intracranial Hemorrhage Complicated by Venous Thromboembolism: A Retrospective Chart Review

S. Schulman, M. Candeloro, J. Gorman, 2023, Thrombosis and Haemostasis.

Two different missense mutations at Arg 178 of the protein C (PROC) gene causing recurrent venous thrombosis

D. Cooper, V. Kakkar, S. Schulman, 1992, Human Genetics.

Pharmacokinetics of Ximelagatran and Relationship to Clinical Response in Acute Deep Vein Thrombosis

Mats O Karlsson, S. Schulman, H. Eriksson, 2005, Clinical pharmacology and therapeutics.

Introduction

S. Schulman, 1999 .

A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome

M. Blostein, S. Schulman, M. Crowther, 2020, Pilot and Feasibility Studies.

Baseline characteristics and management of patients with splanchnic vein thrombosis: Results of an international registry

W. Ageno, E. Grandone, P. Verhamme, 2012 .

Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding.

T. Gomes, M. Mamdani, A. Holbrook, 2019, Thrombosis research.

Graduated compression stockings to treat acute leg pain associated with proximal DVT

S. Kahn, M. Rodger, S. Solymoss, 2014, Thrombosis and Haemostasis.

How Did We Get Here? Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Review

R. Lopes, E. Belley‐Cote, R. Whitlock, 2022, Thrombosis and Haemostasis.

Haemostatic and replacement therapy in von Willebrand disease

S. Schulman, Sam Schulman, 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical history of cancer‐associated splanchnic vein thrombosis

W. Ageno, M. Di Nisio, G. Vidili, 2020, Journal of Thrombosis and Haemostasis.

Abstract 18594: Efficacy of Dabigatran versus Warfarin in Patients With Acute Venous Thromboembolism and Thrombophilia: A Pooled Analysis of RE-COVER™ and RE-COVER™ II

S. Goldhaber, M. Feuring, S. Schulman, 2014 .

Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up

S. Goldhaber, S. Schulman, David Baanstra, 2012 .

Ximelagatran for the secondary prevention of venous thromboembolism

S. Schulman, H. Eriksson, K. Wåhlander, 2005, Thrombosis and Haemostasis.

Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis

C. Bradbury, P. Prandoni, B. Hutton, 2021, Thrombosis and Haemostasis.

Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders

P. Hellström, S. Schulman, P. Lindmarker, 2003, Thrombosis and Haemostasis.

Acquired hemophilia masked by warfarin therapy: report on two cases.

O. Linder, B. Uggla, S. Schulman, 2003, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta‐analysis

J. Douketis, S. Schulman, M. Carrier, 2018, Research and practice in thrombosis and haemostasis.

Long Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis

W. Ageno, F. Dentali, I. Martinelli, 2016 .

Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?

M. Blombäck, S. An, S. Schulman, 2004, Scandinavian journal of clinical and laboratory investigation.

High Versus Ultra-high Purity Factor VIII Concentrate Therapy: Prospective Evaluation of Immunological and Clinical Parameters in HIV Seronegative and Seropositive Hemophiliacs

S. Schulman, D. Bashari, U. Martinowitz, 1994, Thrombosis and Haemostasis.

Psychosocial self-prognosis in relation to mortality and morbidity in hemophiliacs with HIV infection.

T. Theorell, V. Blomkvist, S. Schulman, 1994, Psychotherapy and psychosomatics.

How Did We Get Here? Antithrombotic Therapy after Bioprosthetic Aortic Valve Replacement: A Review

R. Lopes, E. Belley‐Cote, R. Whitlock, 2022, Thrombosis and Haemostasis.

Anticoagulation for stroke prevention in new atrial fibrillation after coronary artery bypass graft surgery.

S. Schulman, J. Delaney, I. Cybulsky, 2015, Thrombosis research.

Oral anticoagulant re-initiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts

R. Al‐Shahi Salman, P. Wells, S. Schulman, 2018, PloS one.

Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism

S. Kahn, D. Anderson, P. Wells, 2016 .

Profile of Patients Diagnosed with Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.

D. Singer, W. Ageno, K. Chee, 2020, The American journal of medicine.

Antithrombotic therapy in the management of hospitalised patients with COVID-19.

S. Schulman, A. Spyropoulos, M. Goldin, 2023, British journal of hospital medicine.

Protein C deficiency and thromboembolism: recurrent mutation at Arg 306 in the protein C gene

D. Cooper, M. Krawczak, V. Kakkar, 1992, Human Genetics.

Should vitamin K antagonist therapy be started simultaneously with parenteral anticoagulation: a meta-analysis?

A. Holbrook, M. Kovacs, S. Schulman, 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A randomized study of alpha‐interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders

S. Schulman, P. Lindmarker, N. Kinnman, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Low PAI‐1 activity in relation to inflammatory parameters, insulin profile and body mass index

B. Wiman, S. Schulman, A. Ågren, 2008, Journal of internal medicine.

Abstract P199: Randomized Comparison of the DAWN AC Computer Program and a Simple Manual Nomogram for Quality of Warfarin Dosing

S. Connolly, J. Eikelboom, S. Schulman, 2011 .

Anticoagulation Control with Daily Low‐Dose Vitamin K to Reduce Clinically Adverse Outcomes and International Normalized Ratio Variability: A Systematic Review and Meta‐Analysis

Per Olav Vandvik, A. Holbrook, D. Witt, 2013, Pharmacotherapy.

Potential for a Virtual Care Model in the Perioperative Management of Anticoagulant Therapy: A 5-Year Retrospective Clinic Review

S. Schulman, James Luke Douketis, 2022, TH Open.

Abstract 12422: Influence of Polypharmacy on the Efficacy And Safety Of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER® and RE-COVER II™

S. Goldhaber, M. Feuring, S. Schulman, 2015 .

The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism.

Vinay Shah, S. Kahn, D. Anderson, 2022, Journal of Thrombosis and Haemostasis.

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

G. Raskob, A. Demchuk, S. Connolly, 2023, Circulation.

Incidence and risk factors for venous thromboembolism in patients with acute spinal cord injury: A retrospective study.

S. Schulman, Siavash Piran, 2016, Thrombosis research.

Needs and challenges among physicians and researchers in thrombosis and hemostasis: Results from an international study

S. Schulman, S. Murray, P. Lazure, 2019, Research and practice in thrombosis and haemostasis.

G. Guyatt, F. Sonnenberg, E. Akl, 2012, Chest.

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

D. Cook, F. Dentali, E. Akl, 2012, Chest.

Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.

U. Mellqvist, R. Pfeiffer, A. Wåhlin, 2009, Blood.

Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

G. Guyatt, D. Cook, M. McDonagh, 2012, Chest.

Advantages and limitations of the new anticoagulants

S. Schulman, 2014, Journal of internal medicine.

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Jason C. Fish, G. Guyatt, A. Holbrook, 2012, Chest.

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

D. Cook, F. Dentali, E. Akl, 2012, Chest.

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

D. Singer, G. Lip, A. Laupacis, 2012, Chest.

EMERGENCY CARE ISSUES IN HEMOPHILIA

S. Schulman, W. Hoots, T. R E A T M E N T O F H E M O P H I L I A, 2007 .

THE BASIC SCIENCE , DIAGNOSIS , AND CLINICAL MANAGEMENT OF VON WILLEBRAND DISEASE

S. Schulman, D. Lillicrap, 2008 .

D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.

J. Douketis, S. Stevens, C. Kessler, 2015, Annals of internal medicine.

Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban

S. Schulman, J. Harenberg, S. Marx, 2012, Journal of thrombosis and haemostasis : JTH.

Recent Advances in Thrombosis and Hemostasis—Part IX

S. Schulman, 2023, Seminars in Thrombosis and Hemostasis.

The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale

J. Douketis, F. Dentali, Vinay Shah, 2017, Thrombosis and Haemostasis.

Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment—A nationwide register‐based study

A. Rosengren, S. Schulman, P. Hansson, 2023, Journal of internal medicine.

Periprocedural Management of Direct Oral Anticoagulants: Comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines

J. Douketis, S. Syed, S. Schulman, 2015, Regional Anesthesia & Pain Medicine.

Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)

S. Kahn, P. Wells, M. Rodger, 2018, Blood.

Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

M. Prins, H. Büller, P. Prandoni, 2019, BMJ.

Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study

W. Ageno, K. Chee, S. Goldhaber, 2021, Journal of Thrombosis and Thrombolysis.

Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

B. Ritchie, S. Schulman, M. Crowther, 2018, Thrombosis and Haemostasis.

Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

B. Ritchie, S. Schulman, M. Crowther, 2018, Thrombosis and Haemostasis.